Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$92.1 million.

  • Prime Medicine's Cash from Investing Activities fell 28299.23% to -$92.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.8 million, marking a year-over-year decrease of 24448.11%. This contributed to the annual value of $68.5 million for FY2024, which is 26586.5% up from last year.
  • Per Prime Medicine's latest filing, its Cash from Investing Activities stood at -$92.1 million for Q3 2025, which was down 28299.23% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Cash from Investing Activities ranged from a high of $50.3 million in Q3 2024 and a low of -$92.1 million during Q3 2025
  • Moreover, its 5-year median value for Cash from Investing Activities was -$4.9 million (2023), whereas its average is -$5.3 million.
  • In the last 5 years, Prime Medicine's Cash from Investing Activities skyrocketed by 40163.66% in 2023 and then crashed by 28299.23% in 2025.
  • Quarter analysis of 5 years shows Prime Medicine's Cash from Investing Activities stood at $12.2 million in 2021, then tumbled by 212.61% to -$13.7 million in 2022, then surged by 401.64% to $41.3 million in 2023, then grew by 16.88% to $48.3 million in 2024, then plummeted by 290.91% to -$92.1 million in 2025.
  • Its Cash from Investing Activities was -$92.1 million in Q3 2025, compared to $2.8 million in Q2 2025 and -$47.7 million in Q1 2025.